(Reuters) – A trial of Pfizer Inc’s experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday. Read full story
Pfizer says antiviral pill cuts risk of severe COVID-19 by 89%
